Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura M Smeaton

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Journal of Infectious Diseases|March 24, 2020
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S SubstudyAshwin Balagopal, Laura M Smeaton, Jeffrey Quinn, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.
The Journal of Infectious Diseases|November 4, 2005
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyDavid W Haas, Laura M Smeaton, Robert W Shafer, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins, Victor De Gruttola, Robert W Shafer, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infectionRobert W Shafer, Laura M Smeaton, Gregory K Robbins, et al.
The Journal of Infectious Diseases|July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender SpectrumLaura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
JAMA|August 15, 2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior, Shahin Lockman, Laura M Smeaton, et al.
Pharmacogenetics and Genomics|June 12, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosisNana Agyemang, Kimberly K Scarsi, Paxton Baker, et al.
Plos Medicine|September 1, 2012
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsThomas B Campbell, Laura M Smeaton, N Kumarasamy, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Infectious Diseases|March 24, 2020
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S SubstudyAshwin Balagopal, Laura M Smeaton, Jeffrey Quinn, et al.
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.
The Journal of Infectious Diseases|November 4, 2005
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyDavid W Haas, Laura M Smeaton, Robert W Shafer, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins, Victor De Gruttola, Robert W Shafer, et al.
The New England Journal of Medicine|December 12, 2003
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infectionRobert W Shafer, Laura M Smeaton, Gregory K Robbins, et al.
The Journal of Infectious Diseases|July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender SpectrumLaura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
JAMA|August 15, 2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi StudyIbou Thior, Shahin Lockman, Laura M Smeaton, et al.
Pharmacogenetics and Genomics|June 12, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosisNana Agyemang, Kimberly K Scarsi, Paxton Baker, et al.
Plos Medicine|September 1, 2012
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsThomas B Campbell, Laura M Smeaton, N Kumarasamy, et al.
Pageof 3